Caribou Biosciences Inc. management misled investors about its financial stability and lead cell therapy product’s outlook, hurting the company and driving down its stock when it announced it had ended certain research and would cut jobs, a shareholder derivative lawsuit said.
Top brass caused Caribou to overhype its CB-010 cell therapy, which is being tested to target a stubborn form of blood cancer, while concealing the company was running out of money to operate, said Alan Moisio’s complaint filed in the US District Court for the Northern District of California.
In June 2024, Caribou said it had presented data from ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.